Tags

Type your tag names separated by a space and hit enter

Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis.
NCI Monogr. 1990NM

Abstract

Reactivation of oral herpes simplex virus (HSV) is very common in patients receiving cytotoxic chemotherapy or bone marrow transplantation. Numerous studies have shown the incidence rate of reactivation to be between 50% and 90% in these populations. Other studies have attempted to correlate oral mucositis and HSV reactivation. From 37% to 68% of all oral mucositis lesions were culture positive in mixed populations of chemotherapy and bone marrow transplant patients. The lesions that were culture positive tended to be more severe than those that were culture negative. These lesions were also atypical in that they involved any perioral and intraoral surface. Patients receiving cytotoxic chemotherapy should have any mucositis lesions evaluated for HSV, including laboratory testing, and should be treated aggressively with acyclovir. Certain groups, such as bone marrow transplant and leukemia patients who are seropositive, should be considered for acyclovir prophylaxis.

Authors+Show Affiliations

University of Texas Health Science Center, San Antonio 78284.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2160612

Citation

Redding, S W.. "Role of Herpes Simplex Virus Reactivation in Chemotherapy-induced Oral Mucositis." NCI Monographs : a Publication of the National Cancer Institute, 1990, pp. 103-5.
Redding SW. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr. 1990.
Redding, S. W. (1990). Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monographs : a Publication of the National Cancer Institute, (9), 103-5.
Redding SW. Role of Herpes Simplex Virus Reactivation in Chemotherapy-induced Oral Mucositis. NCI Monogr. 1990;(9)103-5. PubMed PMID: 2160612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. A1 - Redding,S W, PY - 1990/1/1/pubmed PY - 1990/1/1/medline PY - 1990/1/1/entrez SP - 103 EP - 5 JF - NCI monographs : a publication of the National Cancer Institute JO - NCI Monogr IS - 9 N2 - Reactivation of oral herpes simplex virus (HSV) is very common in patients receiving cytotoxic chemotherapy or bone marrow transplantation. Numerous studies have shown the incidence rate of reactivation to be between 50% and 90% in these populations. Other studies have attempted to correlate oral mucositis and HSV reactivation. From 37% to 68% of all oral mucositis lesions were culture positive in mixed populations of chemotherapy and bone marrow transplant patients. The lesions that were culture positive tended to be more severe than those that were culture negative. These lesions were also atypical in that they involved any perioral and intraoral surface. Patients receiving cytotoxic chemotherapy should have any mucositis lesions evaluated for HSV, including laboratory testing, and should be treated aggressively with acyclovir. Certain groups, such as bone marrow transplant and leukemia patients who are seropositive, should be considered for acyclovir prophylaxis. SN - 0893-2751 UR - https://www.unboundmedicine.com/medline/citation/2160612/Role_of_herpes_simplex_virus_reactivation_in_chemotherapy_induced_oral_mucositis_ L2 - https://medlineplus.gov/cancerchemotherapy.html DB - PRIME DP - Unbound Medicine ER -